Our Milestones

DateMilestone
June 2002Phoenix Eagle Company Pty Ltd founded
July 2002Provisional patent application filed in Australia
July 2003PCT (Patent Co-operation Treaty) patent application filed
July 2005Quadriplegic Centre Report issued –Successful outcomes in the treatment of non-healing pressure ulcers in a Perth hospital from use of OPAL A
Apr 2006First patent granted – in South Africa – without examination
Feb 2008First patent granted after examination – in New Zealand (after 4 examinations)
May 2008Publication of manuscript by Associate Professor Nick Graves of Queensland University of Technology and Dr Elaine Ashby, Senior Medical Consultant of the Taku Group, California, in Wound Practice and Research describing the clinical use of OPAL A in the Quadriplegic Centre, Perth
May 2008Presentation by Associate Professor Geffrey Mitchell of The University of Queensland School of Medicine at the Australian Wound Management Association Conference in Darwin on OPAL A, entitled “Alkalised fruit extract as a potential treatment for chronic ulcers.”
Dec 2008Australian patent granted
July 2009Engagement of Emeritus Professor Keith Brocklehurst and Professor Michael Philpott of Queen Mary College, The University of London to undertake research into the proteolytic activity of the cysteine proteases in OPAL A
Feb 2010Commencement of a proof-of-concept clinical trial for the use of OPAL A in the treatment of venous and pressure ulcers at the Heidelberg Repatriation Hospital in Melbourne
July 2010Appointment of Professor Michael Philpott, lead of the Centre for Cutaneous Research at the Blizard Institute in London, to direct and manage an ongoing program of scientific studies into the properties of OPAL A
Oct 2010Award of a scholarship for a Ph D, supervised by Professor Michael Philpott, to Sreekanth Vootukuri Reddy to investigate the active molecules in OPAL A and their activities
Sep 2011Professor Geoffrey Mitchell granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers
July 2012First U.S. patent issued
Nov 2013Associate Professor Michael Woodward granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers

A number of important milestones relating to the discoveries and inventions made in the course of the work at Queen Mary University of London (as Queen Mary and Westfield College was renamed) have been achieved during the last 5 years, which will be the subject of second generation patent applications. At present this valuable Intellectual Property is Confidential.